Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis

References

• Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–496.
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139.
   PubMed Web of Science ®Google Scholar
• de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144:33–36.
   PubMed Web of Science ®Google Scholar
• Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc. 2004;9:131–135.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol. 2001;145:610–616.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216:260–270.
   PubMed Web of Science ®Google Scholar
• Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25–31.
   PubMed Web of Science ®Google Scholar
• Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
   PubMed Web of Science ®Google Scholar
• Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512–518.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• Kimel M, Bell JA, Sexton C, Revicki DA. HRQL outcomes for assessing effectiveness in clinical trials of biologic agents for psoriasis: a systematic review. Adv Psor Inflam Skin Dis. 2009;1:7–14.
   Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist. 2009;74:65132–65133.
   Google Scholar
• Martin ML, McCarrier KP, Chiou DF, Gordon K, Kimball AB, Van Voorhees AS, et al. Development of a new patient reported measure for assessing symptoms of psoriasis. Abstract presented at EADV. Lisbon, Portugal. October 20–24, 2011a.
   Google Scholar
• Martin ML, Mccarrier KP, Bushnell DM, Gordon K, Chiou CF, Huang X, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patent-reported outcome measure. Abstract presented at EADV. Lisbon, Portugal. October 20–24, 2011b.
   Google Scholar
• Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–1189.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
   PubMedGoogle Scholar
• Ware JE, Kosinski M, Dewey JE. How to score version two of the SF-36 health survey. Lincoln, RI: QualityMetric, Inc, 2000.
   Google Scholar
• Bonifati C, Berardesca E. Clinical outcome measures of psoriasis. Reumatismo. 2007;59:64–67.
   PubMedGoogle Scholar
• Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 1991;124:565–570.
   PubMed Web of Science ®Google Scholar
• Muthén LK, Muthén B. Mplus user's guide. Los Angeles: Muthén & Muthén, 2007.
   Google Scholar
• Thissen D, Chen WH, Bock D. MULTILOG user's guide. Lincolnwood, IL: Scientific Software International, 2002.
   Google Scholar
• Kline R. Principles and pracies of structural equation modeling. 2nd ed. New York: Guilford Press, 2005.
   Google Scholar
• Browne MW, Cudeck R. Alternative ways of assessing model fit. In Bollen KA, Long JS, editors. Testing structural equation models. Beverly Hills, CA: Sage, 1993. p 136–162.
   Google Scholar
• Samejima F. Estimation of latent trait ability using a response pattern of graded scores. Psychomet Monogr. 1969;34:whole No. 17.
   Google Scholar
• Orlando M, Thissen D. Likelihood-based item-fit indices for dichotomous item response theory models. Appl Psychol Meas. 2000;24:50–64.
   Web of Science ®Google Scholar
• Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.
   Web of Science ®Google Scholar
• Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw Hill, 1994.
   Google Scholar
• Hays R, Revicki DA. Reliability and validity (including responsiveness). In Fayers P, Hays R, editors. Assessing quality of life in clinical trials. New York: Oxford University Press, 2005. p 25–39.
   Google Scholar
• Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002;11:193–205.
   PubMed Web of Science ®Google Scholar